Actively Recruiting
Evaluating Safety, Tolerability, and Body Processing of JZP269 Compared to Placebo in Healthy Adults
Led by Jazz Pharmaceuticals · Updated on 2026-11-04
212
Participants Needed
2
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety, tolerability, pharmacokinetics PK, and pharmacodynamics PD of JZP269, an orexin-2 receptor agonist, in healthy male and female adults aged 18 to 55 years. This phase 1, randomized, double-blind, placebo-controlled study aims to understand how the drug behaves in the body, its effects on wakefulness, and the impact of food on its absorption and activity. Participants will be randomly assigned to receive either JZP269 or a matching placebo. The study includes single and multiple ascending doses of the drug to assess its safety and how it is processed in the body. Cerebrospinal fluid samples will be collected to measure drug exposure, and wake-promoting effects will be evaluated using the Maintenance of Wakefulness Test and the Karolinska Sleepiness Scale in sleep-deprived participants. During the study, participants will be monitored for adverse events, and blood samples will be taken up to 48 hours after dosing to analyze pharmacokinetic parameters such as maximum concentration and elimination half-life. Safety assessments include medical evaluations, laboratory tests, and cardiac monitoring. The total participation duration includes dosing days and a safety follow-up period extending up to 7 days after the last dose.
CONDITIONS
Brief Title
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JZP269 in Healthy Male and Female Participants
Research Team
C
Clinical Trial Disclosure & Transparency
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here